Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Trading Statement

7 Jan 2008 07:00

Tarsus Group PLC07 January 2008 7 January 2008 TARSUS GROUP PLC TRADING UPDATE Tarsus Group plc ('Tarsus' or 'the Group'), the international media group withinterests in exhibitions, conferences, publishing and online media hascontinued to trade well in the second half of 2007 with strong performances fromall of its key products. Group like-for-like organic revenue growth for theyear to 31 December 2007 has been 15% and, as a result, the Board expects fullyear 2007 results to be towards the top end of market expectations. Labelexpo Europe, the Group's second largest exhibition, produced revenue growth10% above that of the 2005 event and rebookings for 2009 are already at 90% ofthe total 2007 event. The three important French exhibitions Heavent (event marketing), IP Convergence (IT) and Educatec (education) were all well ahead of2006 and contributed to strong like-for-like organic revenue growth from theFrench division of 14% for the year as a whole. The final medical event of theyear, Anti-Ageing Las Vegas, was a great success with revenues and attendees up35% and 30% respectively over 2006. The development of our emerging markets portfolio was significantly acceleratedwith the November 2007 acquisition of Fairs & Exhibitions Limited, whose keyevent is the Dubai Air Show. This biennial show, which is now the Group's largest, was extremely well received with visitor numbers up nearly 30% from the2005 event to 45,000 and record customer orders in excess of US$100 billion.The event will move to a new purpose-built venue in 2009 which has resulted inrequests for large upgrades in space from major exhibitors. Other emerging market events were China-focused in the second half and our keyevent, the third edition of Labelexpo Asia in Shanghai, saw revenues rise by12% above the 2005 event and visitor numbers by 54%. Rebookings are strong and well ahead of the previous cycle. Caroo, our online business, has continued its strong momentum with like-for-likeorganic revenues up by 21% for the full year. We have appointed a newdivisional CEO in the US to drive growth in that market following theacquisition of the DMS Group in July. Outlook for 2008 The broadening of the Group's base is an important step in underpinning ourability to grow consistently in the years ahead. During 2007 we have continuedto expand the number of sectors served by the Group and made good progress in diversifying our revenues geographically. Average emerging market revenues forthe 2007/2008 cycle are expected to be approximately 16% of the total up from5% for the 2005/2006 cycle. The Group is strongly second half weighted and, with the major Labelexpo showreturning to the US from Europe in 2008, dollar exposure will be higher than in2007. Our significant events in the first quarter of 2008 - the US Off-Price show, the Mod'Amont clothing accessories event in Paris and GESS (a neweducational show in Dubai) - are developing extremely well. Overall, forwardbookings are strong and the Board remains confident that 2008 will be anotheryear of strong like-for-like growth for the Group. The Group expects to announce its preliminary results for the year to 31December 2007 on 3 March 2008. Ends For further information please contact: Tarsus Group plc: Douglas Emslie: Group Managing Director: Tel 020 8846 2700 Media: Matthew Moth :Madano Partnership: Tel: 020 7593 4000 Investors: Neville Harris : IRFocus: Tel: 020 7593 4215 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Dec 20164:35 pmRNSHolding(s) in Company
8th Dec 20164:33 pmRNSHolding(s) in Company
8th Dec 20164:31 pmRNSHolding(s) in Company
8th Dec 20164:29 pmRNSHolding(s) in Company
8th Dec 20167:00 amRNSCompletion of Acquisition
7th Dec 20169:00 amRNSAdmission of Placing Shares
5th Dec 201612:30 pmRNSCompletion of Placing
5th Dec 20167:00 amRNSProposed Placing and Acquisition
1st Dec 201610:46 amRNSTotal Voting Rights
22nd Nov 20167:00 amRNSCapital Markets Event and Trading Update
9th Nov 20163:19 pmRNSBlock listing Interim Review
31st Oct 20169:52 amRNSTotal Voting Rights
13th Oct 20167:24 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSTrading Update
30th Sep 20169:53 amRNSTotal Voting Rights and Capital
1st Sep 201612:09 pmRNSTotal Voting Rights
15th Aug 20165:28 pmRNSInterim financial statements
9th Aug 20166:11 pmRNSHolding(s) in Company
29th Jul 201612:10 pmRNSTotal Voting Rights and Capital
27th Jul 20167:00 amRNSHalf-year Report
11th Jul 20161:30 pmRNSApplication for Admission
5th Jul 20161:12 pmRNSHolding(s) in Company
30th Jun 201612:28 pmRNSTotal Voting Rights
21st Jun 20164:42 pmRNSDirector/PDMR Shareholding
20th Jun 20164:00 pmRNSResult of AGM
7th Jun 20161:15 pmRNSDirector/PDMR Shareholding
3rd Jun 20162:58 pmRNSScrip Dividend Circular (the "Circular")
31st May 201611:59 amRNSTotal Voting Rights and Capital
17th May 20163:08 pmRNSNotice of 2016 Annual General Meeting
17th May 20167:00 amRNSTrading Update
11th May 20167:00 amRNSDirector/PDMR Shareholding
9th May 20163:43 pmRNSBlock Listing Six Monthly Return
29th Apr 20164:14 pmRNSTotal Voting Rights
31st Mar 20162:25 pmRNSTotal Voting Rights
31st Mar 20162:24 pmRNSDirector/PDMR Shareholding
21st Mar 20163:11 pmRNS2015 Annual Report
8th Mar 20165:55 pmRNSDirector/PDMR Shareholding
3rd Mar 20164:47 pmRNSDirector/PDMR Shareholding
2nd Mar 20167:00 amRNSFinal Results
2nd Feb 20163:48 pmRNSTotal Voting Rights and Capital
25th Jan 20161:05 pmRNSApplication for Admission
12th Jan 20167:00 amRNSYear-end trading update
31st Dec 20159:25 amRNSTotal Voting Rights
14th Dec 20155:07 pmRNSScrip dividend circular
8th Dec 20157:00 amRNSCapital markets presentation
2nd Dec 20153:49 pmRNSDirector/PDMR Shareholding
30th Nov 20154:35 pmRNSTotal Voting Rights
11th Nov 201510:00 amRNSBlock Listing Six Monthly Return
30th Oct 20153:22 pmRNSDirector/PDMR Shareholding
30th Oct 20153:20 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.